Exenatide trials for the treatment of type 2 diabetes;Ensayos clinicos de exenatida y su rol en el tratamiento de la diabetes tipo

Medicina

Volumn 69, Issue 4, 2009, Pages 447-457

  Lando, Laura Fernandez ^a,b   Casellini, Carolina M ^a  

^a CEMIC   (Argentina)

^b NONE   (Argentina)

Author keywords

Exenatide; Incretin effect; Treatment; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INCRETIN; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; PLACEBO; SULFONYLUREA; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; WEIGHT REDUCTION; GLUCOSE BLOOD LEVEL; METABOLISM; PHASE 3 CLINICAL TRIAL;

BLOOD GLUCOSE; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PEPTIDES; VENOMS;

EID: 70349573049     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258
2. American Diabetes Association, Inc., Diabetes 2001 vital statistics. Prevalence of Diabetes Worldwide: Country and Regional Data. World Health Organization. En: http://www.who.int/diabetes/facts/world-figures/en/: consultado: 27/07/2008.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospec-tive observational study. BMJ. 2000; 321: 405-412 (Pubitemid 30609442)
5. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004; 27: 17-20.
6. Dunning BE, Foley JE, Ahren B. Alfa cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005; 48: 1700-1713 (Pubitemid 41317822)
7. DeFronzo RA and Mandarino LJ. Pathogenesis of type 2 Diabetes (Chapter 9). In: Goldfine ID and Rushakoff RJ (eds). Diabetes and Carbohydrate Metabolism. Enero 20, 2003 http://www.endotext.org/diabetes/diabetes6/ diabetesframe6.htm: consultado: 27/07/2008.
8. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723 (Pubitemid 32755966)
9. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52. (Pubitemid 16162741)
10. Amylin Pharmaceuticals I. Byetta (exenatide injection): prescribing information [online]. En: http://www.byetta.com Consultado 19/07/2008.
11. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076-1082
12. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46:1954-1962
13. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940 (Pubitemid 37205571)
14. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830 (Pubitemid 34233752)
15. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744 (Pubitemid 23218642)
16. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987; 84: 3434-3438 (Pubitemid 17085418)
17. Komatsu R, Matsuyama T, Namba M, et al. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 1989; 38: 902-905 (Pubitemid 20022397)
18. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 2719-2725 (Pubitemid 36733545)
19. Gutzwiller JP, Goke B, Drewe J, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44: 81-86 (Pubitemid 29143284)
20. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276: R1541-4. (Pubitemid 29249681)
21. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003; 144: 5145-5148
22. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 2004; 47: 4135-4141 (Pubitemid 39045417)
23. Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004; 145: 2653-2659
24. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131
25. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 2006; 7: 367-374
26. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181 (Pubitemid 40674548)
27. Byetta (exenatide) [package insert]. San Diego, Calif.: Amylin Pharmaceuticals and Eli Lilly and Company; 2008
28. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4); a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004; 117: 77-88. (Pubitemid 38045329)
29. Linnebjerg H, Kothare P, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64: 317-327 (Pubitemid 47283860)
30. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin 4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089
31. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin 4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 1282-1290 (Pubitemid 36121100)
32. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53: 2397-2403 (Pubitemid 39145595)
33. Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 2005; 45: 570-577 (Pubitemid 40562948)
34. Linnebjerg H, Park S, Kothare P, et al. Exenatide delays gastric emptying and reduces postprandial glucose in type 2 diabetes [abstract no. 0223]. Diabetologia 2006; 49 (Suppl. 1): 140.
35. Stonehouse A, Okerson T, Kendall D and Maggs D. Emerging incretin-based therapies for Type 2 Diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev 2008; 4: 101-109
36. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003; 17: 161-171 (Pubitemid 36183142)
37. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286
38. Fehse FC, Trautmann ME, Holst JJ, et al. Exenatide augments first and second phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90: 5991-5997
39. Lupi R, Mancarella R, Del Guerra S, et al. Effects of exendin-4 on islets from type 2 diabetes patients. Diabetes, Obesity and Metabolism 2008; 515-519
40. Triplitt C, Chiquette E. Exenatide: From the Gila Monster to the Pharmacy. J Am Pharm Assoc. 2006; 46: 44-55.
41. Kothare PA, Soon DK, Linnebjerg H, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005; 45: 1032-1037 (Pubitemid 41192362)
42. Risto S. Cvetkovíc and Plosker GL. Exenatide: A Review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea) Drugs 2007; 67: 935-954 (Pubitemid 46607392)
43. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. For the exenatide 113 clinical study group: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635
44. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100
45. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091 (Pubitemid 40616617)
46. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007; 146: 477-485 (Pubitemid 351650556)
47. Moretto TJ, Milton D, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized Double-Blind, Placebo-Controlled, Parallel-Group Study. Clin Ther 2008; 30: 1-13.
48. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. GWAA study group: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569 (Pubitemid 41476552)
49. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non inferiority study. Diabetologia 2007; 50: 259-267
50. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29: 2333-2348 (Pubitemid 350298125)
51. Buse JB, MacConell L, Stonehouse AH, et al. Exenatide maintained glycemic control with associated weight reduction over three years in patients with type 2 diabetes. Diabetes 2007; 56 (Suppl 1): A73.
52. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447 (Pubitemid 44349236)
53. Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007; 29: 139-153
54. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA, 2007; 298: 194-206. (Pubitemid 47057766)
55. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-1493 (Pubitemid 46871159)
56. Forti A, García-García E, Yu MB, Jiménez MC, Brodows RG and Oliveira JH. Efficacy and safety of exenatide administered before the two largest daily meals of latin american patients with type 2 diabetes. Curr Med Res Opin 2008; 24: 2437-2447
57. Malone J. Medical letter. 29 Aug 2008. Data on File, Eli Lilly.
58. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012 (Pubitemid 29254858)
59. DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621
60. Monnier L, Colett C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30: 263-269 (Pubitemid 46198328)
61. American Diabetes Association. Consensus statement. Postprandial blood glucose Diabetes Care 2001; 24: 775-778